MX2020002156A - Composiciones y metodos para el uso anti viral de analogos y mimeticos de lisina sintetica. - Google Patents
Composiciones y metodos para el uso anti viral de analogos y mimeticos de lisina sintetica.Info
- Publication number
- MX2020002156A MX2020002156A MX2020002156A MX2020002156A MX2020002156A MX 2020002156 A MX2020002156 A MX 2020002156A MX 2020002156 A MX2020002156 A MX 2020002156A MX 2020002156 A MX2020002156 A MX 2020002156A MX 2020002156 A MX2020002156 A MX 2020002156A
- Authority
- MX
- Mexico
- Prior art keywords
- synthetic lysine
- mimetic
- viral infections
- lysine analog
- viral
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Dispersion Chemistry (AREA)
- Otolaryngology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762550656P | 2017-08-27 | 2017-08-27 | |
| US201862664555P | 2018-04-30 | 2018-04-30 | |
| PCT/US2018/046023 WO2019045989A1 (en) | 2017-08-27 | 2018-08-09 | METHODS AND COMPOSITIONS FOR THE ANTIVIRAL USE OF LYSINE SYNTHETIC ANALOGUES AND MIMETICS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020002156A true MX2020002156A (es) | 2020-07-20 |
Family
ID=65525881
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020002156A MX2020002156A (es) | 2017-08-27 | 2018-08-09 | Composiciones y metodos para el uso anti viral de analogos y mimeticos de lisina sintetica. |
| MX2023009499A MX2023009499A (es) | 2017-08-27 | 2020-02-26 | Composiciones y metodos para el uso anti viral de analogos y mimeticos de lisina sintetica. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023009499A MX2023009499A (es) | 2017-08-27 | 2020-02-26 | Composiciones y metodos para el uso anti viral de analogos y mimeticos de lisina sintetica. |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11413279B2 (enExample) |
| EP (1) | EP3672584A4 (enExample) |
| JP (3) | JP2020531586A (enExample) |
| KR (1) | KR102706114B1 (enExample) |
| CN (1) | CN111315374A (enExample) |
| AU (2) | AU2018324427B2 (enExample) |
| BR (1) | BR112020003735A2 (enExample) |
| CA (1) | CA3073685A1 (enExample) |
| MX (2) | MX2020002156A (enExample) |
| WO (1) | WO2019045989A1 (enExample) |
| ZA (1) | ZA202001472B (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3156617A1 (en) * | 2019-10-29 | 2021-05-06 | W. Paul Stewart | Synergistic combinations of synthetic lysine analogs, derivatives, mimetics, or prodrugs and pharmaceutical agents for enhanced efficacy |
| WO2021162879A1 (en) * | 2020-02-14 | 2021-08-19 | Tranexamic Technologies, Llc | Methods and compositions for antimicrobial use of synthetic lysine analogs, derivatives, mimetics, and prodrugs |
| JP2022132181A (ja) * | 2021-02-26 | 2022-09-07 | ライオン株式会社 | コロナウイルスの細胞侵入抑制剤 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0789764B1 (en) * | 1994-10-28 | 2002-01-09 | Vitaleech Bioscience N.V. | A novel family of protease inhibitors, and other biologic active substances |
| WO2000037071A1 (en) * | 1998-12-21 | 2000-06-29 | Aps Kbus 8 Nr. 4788 | Topical treatment of skin disease |
| ES2156731B1 (es) * | 1999-05-31 | 2002-02-16 | Grifols Grupo Sa | Utilizacion del acido tranexamico para la preparacion de una composicion de fibrinogeno humano. |
| US7056947B2 (en) | 2002-07-05 | 2006-06-06 | Georgia Tech Research Corp. | Aza-peptide epoxides |
| JP4600882B2 (ja) * | 2002-10-11 | 2010-12-22 | 第一三共株式会社 | 抗インフルエンザウイルス剤 |
| JP2008115168A (ja) * | 2006-10-12 | 2008-05-22 | Daiichi Sankyo Healthcare Co Ltd | 抗アデノウイルス剤 |
| JP5730211B2 (ja) * | 2008-11-20 | 2015-06-03 | バイオジェン アイデック エムエー インコーポレイティドＢｉｏｇｅｎ Ｉｄｅｃ Ｉｎｃ． | ウイルスのアルギニン不活化 |
| JP2010189301A (ja) * | 2009-02-17 | 2010-09-02 | Toshihito Eto | 新型インフルエンザ感染症に対する医薬組成物およびその利用 |
| US20120082677A1 (en) * | 2010-10-01 | 2012-04-05 | Sherif Salah Abdul Aziz | Compositions for the treatment of hcv and hbv |
| US20140271923A1 (en) * | 2013-03-14 | 2014-09-18 | Christopher Brian Reid | Compositions & formulations for preventing and treating chronic diseases that cluster in patients such as cardiovascular disease, diabetes, obesity, polycystic ovary syndrome, hyperlipidemia and hypertension, as well as for preventing and treating other diseases and conditions |
| CN103405384B (zh) * | 2013-09-01 | 2015-05-13 | 吴静 | 氨甲环酸的药物组合物 |
-
2018
- 2018-08-09 JP JP2020532845A patent/JP2020531586A/ja not_active Withdrawn
- 2018-08-09 CN CN201880070088.0A patent/CN111315374A/zh active Pending
- 2018-08-09 AU AU2018324427A patent/AU2018324427B2/en active Active
- 2018-08-09 WO PCT/US2018/046023 patent/WO2019045989A1/en not_active Ceased
- 2018-08-09 US US16/610,504 patent/US11413279B2/en active Active
- 2018-08-09 CA CA3073685A patent/CA3073685A1/en active Pending
- 2018-08-09 MX MX2020002156A patent/MX2020002156A/es unknown
- 2018-08-09 BR BR112020003735-4A patent/BR112020003735A2/pt unknown
- 2018-08-09 EP EP18850491.4A patent/EP3672584A4/en active Pending
- 2018-08-09 KR KR1020207008860A patent/KR102706114B1/ko active Active
-
2020
- 2020-02-26 MX MX2023009499A patent/MX2023009499A/es unknown
- 2020-03-09 ZA ZA2020/01472A patent/ZA202001472B/en unknown
-
2022
- 2022-05-25 US US17/824,602 patent/US20220288050A1/en not_active Abandoned
-
2023
- 2023-05-30 JP JP2023088440A patent/JP2023123440A/ja not_active Withdrawn
-
2024
- 2024-06-06 AU AU2024203839A patent/AU2024203839A1/en active Pending
-
2025
- 2025-08-01 JP JP2025129144A patent/JP2025166032A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2023009499A (es) | 2023-08-23 |
| CN111315374A (zh) | 2020-06-19 |
| KR102706114B1 (ko) | 2024-09-11 |
| JP2023123440A (ja) | 2023-09-05 |
| WO2019045989A1 (en) | 2019-03-07 |
| US11413279B2 (en) | 2022-08-16 |
| BR112020003735A2 (pt) | 2020-09-01 |
| AU2018324427A1 (en) | 2020-04-09 |
| KR20200052310A (ko) | 2020-05-14 |
| CA3073685A1 (en) | 2019-03-07 |
| EP3672584A4 (en) | 2021-05-05 |
| ZA202001472B (en) | 2022-05-25 |
| AU2018324427B2 (en) | 2024-03-07 |
| JP2020531586A (ja) | 2020-11-05 |
| EP3672584A1 (en) | 2020-07-01 |
| US20200323837A1 (en) | 2020-10-15 |
| AU2024203839A1 (en) | 2024-06-27 |
| US20220288050A1 (en) | 2022-09-15 |
| JP2025166032A (ja) | 2025-11-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2019003892A1 (es) | Nuevos derivados de azaquinolina. | |
| EA202091114A1 (ru) | Новые высокоактивные пиразолопиперидин-замещенные индол-2-карбоксамиды, активные против вируса гепатита в (hbv) | |
| CO2019010295A2 (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| CO2019013042A2 (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| EA201791903A1 (ru) | β-D-2'-ДЕЗОКСИ-2'-α-ФТОР-2'-β-C-ЗАМЕЩЕННЫЕ-2-МОДИФИЦИРОВАННЫЕ-N6-ЗАМЕЩЕННЫЕ ПУРИНОВЫЕ НУКЛЕОТИДЫ ДЛЯ ЛЕЧЕНИЯ ВЫЗВАННЫХ HCV ЗАБОЛЕВАНИЙ | |
| UY37480A (es) | Nuevos derivados de quinolina | |
| CL2020001145A1 (es) | Nuevas indol-2-carboxamidas sustituidas con amino-tiazol, de alta actividad, activas contra el virus de la hepatitis b (vhb). | |
| UY37831A (es) | Nuevos derivados de quinolina | |
| CO2019010292A2 (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| CO2018008421A2 (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| BR112018009009A2 (pt) | terapia combinada de um inibidor de formação de capsídeo hbv e um interferon | |
| ECSP19083640A (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| BR112017000246A2 (pt) | composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, e, uso de um composto ou de um sal | |
| AR105493A1 (es) | Inhibidor de la isocitrato deshidrogenasa mutada idh1 r132h | |
| MX2023009499A (es) | Composiciones y metodos para el uso anti viral de analogos y mimeticos de lisina sintetica. | |
| MX2017005134A (es) | Tratamiento del cáncer con inmunoestimuladores. | |
| HRP20220011T1 (hr) | Nova stabilna formulacija za fxia protutijela | |
| MX2022002196A (es) | Composición de liberación retardada de niclosamida y uso antiviral de la misma. | |
| BR112014028130A2 (pt) | Sal de cloridrato de um peptídeo, composição farmacêutica, uso de um sal de cloridrato, uso de uma composição farmacêutica, e, método para evitar ou tratar alergia a gatos | |
| BR112016021000A2 (pt) | Composições e métodos para prevenir ou tratar dis-função crônica do aloenxerto de pulmão (clad) e fi-brose pulmonar idiopática (ipf) | |
| BR112018073858A2 (pt) | métodos para tratamento de infecções pelo vírus da hepatite b usando inibidores de ns5a, ns5b ou ns3 | |
| EA201691792A1 (ru) | Фармацевтические составы на основе вилдаглиптина | |
| EA201791525A2 (ru) | Соединения для лечения блокады ремиелинизации при заболеваниях, связанных с экспрессией белка оболочки herv-w | |
| MX2021012739A (es) | Retrasar el efecto pico y/o prolongar la duracion de la respuesta. | |
| BR112022023135A2 (pt) | Amidas tricíclicas substituídas, análogos das mesmas e métodos que usam as mesmas |